Results 121 to 130 of about 60,513 (321)

Patient‐Reported Oral Symptoms and Their Impact on Well‐Being After Haematopoietic Cell Transplantation

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase.
Kristina Skallsjö   +14 more
wiley   +1 more source

The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis

open access: yesTransplant Infectious Disease, EarlyView.
This single‐center retrospective cohort study on 300 allogeneic hematopoietic stem cell transplant recipients from January 2017 to May 2020, in which posaconazole modified release was the most common primary antifungal prophylaxis, demonstrated a breakthrough invasive fungal disease (bIFD) rate of 9%, with associated significant all‐cause mortality at ...
Shio Yen Tio   +7 more
wiley   +1 more source

Digital PCR - Methods and Protocols

open access: yesEuropean Journal of Histochemistry, 2019
Sensitivity, reproducibility, precision and accuracy are recurring words in this book. Indeed, digital PCR (dPCR) represents a major step forward in the quantification of nucleic acids. In this field, for many years it has been used the quantitative PCR (
Paolo Catarsi
doaj   +1 more source

A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies [PDF]

open access: yes, 2016
The Src family kinase (SFK)member SRC is amajor target in drug development because it is activated in many human cancers, yet deleterious SRC germline mutations have not been reported. We used genome sequencing and Human Phenotype Ontology patient coding
,   +43 more
core   +1 more source

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

open access: yesAmerican journal of hematology/oncology, 2020
The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate.
N. Polverelli   +28 more
semanticscholar   +1 more source

Localized Tuberculosis and Myelofibrosis with Myeloid Metaplasia : An extremely unusual presentation [PDF]

open access: yes, 1996
Myelofibrosis with myeloid metaplasia (MMM) is usually considered primary agnogenic, however, it may be secondary to various diseases, The association of tuberculosis with MMIM is exceedingly rare, however, the pathogenetic relationship between the two ...
Muzaffar, Suhail
core   +1 more source

Management Strategies for Refractory Esophageal Varices

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Refractory esophageal varices that are difficult to control or unresponsive to endoscopic treatment remain a major clinical challenge in the management of portal hypertension. This review provides a comprehensive overview of treatment strategies for these cases, along with a comparative analysis of the American Association for the Study of ...
Keita Maki, Hiroaki Haga, Yoshiyuki Ueno
wiley   +1 more source

P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS

open access: yesHemaSphere, 2022
R. Campanelli   +10 more
doaj   +1 more source

Primary autoimmune myelofibrosis: a report of three cases and review of the literature

open access: yesTurkish Journal of Hematology, 2009
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj  

Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis

open access: yesОнкогематология, 2016
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity ...
M. S. Fominykh   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy